Step 1: Identify the requirement. The question asks for an agent that raises the platelet count after chemotherapy-induced (myelosuppressive) thrombocytopenia, i.e. a thrombopoietic growth factor.
Step 2: Oprelvekin is recombinant interleukin-11. It stimulates megakaryocyte maturation and platelet production, and is specifically approved to prevent severe thrombocytopenia after myelosuppressive chemotherapy.
Step 3: Eliminate the distractors. Iron dextran corrects iron deficiency anaemia, not platelet counts. Tranexamic acid is an antifibrinolytic that reduces bleeding but does not raise platelets. Erythropoietin stimulates red cell production, addressing anaemia, not thrombocytopenia.
Step 4: Hence the correct answer is oprelvekin (interleukin-11), option B.